NAV Financing in Private Equity: How GPs Borrow Against Their Whole Portfolio

Private equity funds borrow money in three structurally different ways. Most analysts only learn about the first two.

The first is portfolio-company debt. A PE-owned business issues term loans and high-yield bonds at the operating-company level, secured against its own cash flows and assets. This is the leveraged-buyout debt every analyst learns to model in week two of training. It is what makes an LBO an LBO.

The second is subscription-line debt. A PE fund borrows against the uncalled commitments of its LPs, using a working-capital revolver that the fund draws on instead of issuing capital calls. The fund repays the line by calling capital from LPs on a quarterly cadence. The line is short-dated, very low-priced, and ubiquitous.

The third is NAV financing. And NAV financing is what every PE analyst, LP advisor, and fund-finance banker is suddenly arguing about in 2025 and 2026.

This primer is about that third category. What NAV financing is, why it has tripled in size, how the deal mechanics work, why LPs are increasingly hostile to it, and what an analyst needs to know.

The definition

NAV financing, also known as NAV lending, fund-level financing, or a GP-led NAV facility, is a loan to a private equity fund secured against the net asset value of the fund’s underlying portfolio companies. Unlike portfolio-company debt, the loan does not sit on any single company’s balance sheet. Unlike subscription lines, the loan is not secured against LP capital commitments. It is secured against the diversified pool of equity stakes the fund holds.

In a typical structure, a GP whose Fund VI holds equity stakes in twelve portfolio companies, with an aggregate fair-value mark of $4 billion, pledges those stakes to a NAV lender as collateral. The NAV lender extends a loan of, say, $500 million at a 12.5% loan-to-value (LTV) ratio. The fund uses the proceeds. The lender’s recourse is to the underlying equity stakes if the fund cannot repay.

Why this product exploded

The use cases for NAV financing existed for years before 2020, but the market was modest. The product became a major industry in the period from 2022 onward, for one structural reason: PE exits slowed dramatically as base rates rose and the M&A market repriced. Funds that had expected to harvest their portfolios on a normal cadence found themselves stuck with assets that were difficult to sell at acceptable prices.

This created intense demand for fund-level liquidity. GPs needed money to:

• Use case 1

  Fund LP distributions

  LPs expect a steady cadence of distributions. When exits stall, GPs use NAV loans to fund distributions out of borrowed money, keeping LP cash flow predictable.

• Use case 2

  Finance follow-on investments

  A portfolio company has an attractive bolt-on acquisition. The fund's dry powder is committed elsewhere. A NAV loan finances the follow-on at the fund level.

• Use case 3

  Support struggling assets

  A portfolio company breaches a covenant or needs a balance-sheet rescue. Equity-funding it would dilute the fund's other LPs disproportionately. A NAV loan injects capital without dilution.

• Use case 4

  Refinance portfolio-company debt

  Several portfolio companies have maturing debt at higher cost than a fund-level facility would carry. NAV financing pays them down and substitutes a single fund-level liability at lower aggregate rate.

The economic logic is straightforward. A fund with $4B of NAV at fair value can support a $500M-$800M secured loan at modest LTV, because the lender knows that even in stress scenarios the underlying equity stakes are unlikely to collapse to zero across a diversified portfolio. The diversification at the portfolio level is what unlocks the borrowing at the fund level.

How the deal mechanics work

A NAV financing transaction goes through a fairly standard sequence:

1. The GP selects collateral

The fund identifies which portfolio companies will sit inside the borrowing-base collateral pool. Typically the more mature, higher-quality assets are included; the riskier or earlier-stage assets are excluded. A diversified pool of 8 to 15 companies is typical.

2. Lenders run portfolio-level diligence

NAV lenders are specialist credit funds. The major players include 17Capital (Oaktree), HPS Investment Partners, Pemberton, Crestline, Ares, Whitehorse Liquidity Partners, and several large bank fund-finance desks. They review the fund’s quarterly NAV reports, the underlying company financials, and the GP’s valuation methodology in depth.

3. The lender sets an LTV cap and pricing

Conservative facilities sit at 10% to 15% loan-to-NAV. More aggressive ones extend to 20% to 25%. Pricing on senior NAV loans in 2024 to 2025 typically ranges from SOFR + 500bps to SOFR + 800bps depending on portfolio quality, with origination fees of 1% to 3%.

4. The borrower covenants are negotiated

Standard NAV facility covenants include:

5. Closing and ongoing reporting

The facility closes. The GP draws as needed. Quarterly NAV marks update the LTV calculation. The lender monitors the portfolio, and the cash sweeps kick in if the LTV breaches the covenant.

Why LPs are increasingly hostile

If the use cases are clearly valuable to the GP, why are LPs (and increasingly the financial press) pushing back on NAV financing?

The pushback has several distinct strands:

1. Distribution-financed-with-debt distorts net IRR

A traditional PE fund distributes cash from realised exits. The internal rate of return (IRR) calculation reflects actual cash returns. When a fund instead distributes cash funded by NAV borrowings, the LP receives the cash earlier than the underlying exits would have generated. The IRR is mechanically higher because the distribution is earlier, even though the underlying value creation has not changed.

LPs argue this is a form of accounting engineering: the GP is converting an extended hold period into a shorter reported hold period by using leverage to advance the cash, and earning carry on the inflated IRR. Sophisticated LPs adjust their reporting to back out the effect, but many do not.

2. The cost is high

Senior NAV loans at SOFR + 600bps cost roughly 11% to 12% in 2024 to 2025. That is a material drag on net returns. If the fund uses NAV financing to distribute cash that earns its LPs no additional return between distribution and ultimate exit, the cost is a pure deadweight loss to fund-level economics.

3. Cross-collateralisation introduces new risk

Pledging the entire portfolio as collateral means that a problem in one company can trigger covenant breaches affecting the entire portfolio. A defaulted facility could force the lender to seize collateral across the fund, value-destroying for all LPs.

4. The GP can use the facility to delay difficult decisions

A portfolio company that should be sold at a loss or written down can be propped up with NAV-financed equity injections. This delays the recognition of the loss and protects the GP’s reported track record. LPs argue this is a misuse.

5. LP consent rights are often weak

Many fund agreements do not explicitly contemplate NAV financing. GPs argue the facilities are within their general powers. LPs argue they are a structural change requiring explicit consent. Industry bodies including the Institutional Limited Partners Association (ILPA) issued guidelines in 2024 calling for explicit LP consent or LPAC approval on NAV facilities.

The market in 2025 and 2026

NAV financing has institutionalised quickly. Annual originations exceeded $50 billion in 2024 with strong continued growth in 2025. Major specialist lenders raised dedicated NAV financing funds. Large banks built dedicated fund-finance desks for NAV products. The product is now considered standard PE infrastructure.

At the same time, LP pushback intensified. In late 2024 and through 2025, several major pension fund LPs publicly stated they would not invest in new PE funds that intended to use NAV financing without explicit advance disclosure and LPAC consent. ILPA published structured guidance pushing GPs toward more transparent disclosure. The trade press now covers individual large facilities with significant editorial scrutiny.

The likely equilibrium: NAV financing remains a permanent product, but with stronger LP governance, clearer disclosure standards, and probably tighter use-case restrictions. The era of GPs putting on NAV facilities without LP awareness is ending.

How NAV financing differs from subscription lines

Analysts often confuse NAV financing with the much older subscription-line product. They are entirely different.

Feature	Subscription line	NAV financing
Collateral	LP capital commitments	Portfolio company equity stakes
Loan-to-value	Up to 90% of uncalled commitments	10% to 25% of NAV
Use case	Bridge capital calls for new investments	Distributions, follow-ons, refinancing
Tenor	364 days revolver, renewable	3 to 5 year term
Pricing	SOFR + 175 to 250bps	SOFR + 500 to 800bps
Lender	Large commercial banks	Specialist credit funds
LP visibility	Moderate, often disclosed	Often poorly disclosed
Effect on IRR	Inflates near-term IRR by delaying capital calls	Inflates IRR by accelerating distributions with debt

Both products inflate net IRR through accounting effects. Subscription lines accelerate the apparent capital call timing; NAV financing accelerates apparent distributions. Both are accepted PE practice, but both are increasingly disclosed and adjusted-for by sophisticated LPs.

What an analyst should know

For an analyst working on or around PE:

1. Understand the three layers of leverage. Portfolio company debt, subscription lines, NAV financing. Each operates differently. Each has different risks and different LP implications.

2. Read the fund agreement. Whether NAV financing is permitted, what consent is required, what disclosure is mandated, all live in the LPA. Different funds have very different rules.

3. Adjust net IRR for fund-level financing. If you are evaluating a GP’s track record, back out the effect of subscription lines and NAV financing to get a true gross-of-financing IRR. Sophisticated LP advisors do this routinely.

4. Know the major lenders. 17Capital, HPS, Pemberton, Whitehorse, Crestline, Ares, and the major bank fund-finance desks. Each has a different appetite and different terms.

5. Watch the disclosure trend. ILPA guidelines, public LP statements, and regulator focus all point toward tighter NAV facility disclosure over the next several years. The market structure is still evolving.

NAV financing is the structural innovation that will define PE leverage in this cycle. Understanding it cold is foundational for any analyst, LP advisor, or M&A banker working in or around the asset class.

Frequently asked questions

What is NAV financing in private equity?

NAV financing is a loan to a private equity fund secured against the net asset value of the fund’s underlying portfolio companies. The lender’s collateral is the diversified pool of equity stakes the fund holds, not any single company’s balance sheet and not the LPs’ capital commitments.

How does NAV financing differ from a subscription line?

A subscription line is a short-term revolver secured against LP capital commitments and used to bridge new investments. NAV financing is a term loan secured against the fund’s portfolio of existing equity stakes and used for distributions, follow-on investments, or portfolio support. The two products serve different purposes and have very different pricing and risk profiles.

How big is the NAV financing market?

The market reached roughly $50 billion of annual originations by 2024, having grown roughly 3x from 2020 levels. Continued growth has pushed the cumulative outstanding to well over $100 billion globally by 2025.

Who are the major NAV financing lenders?

The major specialist credit lenders include 17Capital (acquired by Oaktree), HPS Investment Partners, Pemberton Asset Management, Whitehorse Liquidity Partners, Crestline Investors, and Ares Management. Several large banks including JPMorgan, Goldman Sachs and Citi also have dedicated fund-finance desks offering NAV facilities.

Why are LPs critical of NAV financing?

LPs argue that NAV financing inflates reported net IRR by accelerating distributions with borrowed money, adds fund-level leverage on top of portfolio-company leverage, and can be used to delay write-downs of struggling assets. The Institutional Limited Partners Association published guidelines in 2024 calling for greater transparency and LPAC consent on NAV facilities.

What is the typical loan-to-value ratio on a NAV facility?

Conservative facilities sit at 10% to 15% loan-to-NAV. More aggressive structures extend to 20% to 25%. Above 25% LTV the credit risk becomes meaningfully higher and pricing widens substantially.

Is NAV financing legal under standard fund agreements?

In most cases yes, but it depends on the specific fund agreement. Many older fund agreements did not contemplate NAV facilities explicitly. GPs typically argue NAV financing falls within general borrowing authority; LPs increasingly argue it requires explicit consent. The market has moved toward LPAC approval as a standard requirement on new facilities.